GSA Capital Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

GSA Capital Partners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78,729	Closed	-$473K	–	2078
2022 Q4	$473K	Sell	78,729 -55,625	-41%	-$304K	0.06%	638
2022 Q3	$782K	Buy	+134,354	New	+$837K	0.1%	277
2015 Q1	–	Sell	-1,621	Closed	-$38K	–	2352
2014 Q4	$38K	Buy	+1,621	New	+$37.5K	﹤0.01%	1644

Other funds holding CTIC

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GSA Capital Partners's CTIC Position: Q1 2023 in Review

GSA Capital Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 78,729 shares — an estimated $473K sold.

GSA Capital Partners first reported a position in CTIC in Q4 2014 and held it in 3 quarters. The position peaked at $782K in Q3 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

GSA Capital Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
GSA Capital Partners sold 78,729 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $473K.
GSA Capital Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 3 quarters.
GSA Capital Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $782K in Q3 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.